Cosmo Pharmaceuticals2023年年度报告.pdf

《Cosmo Pharmaceuticals2023年年度报告.pdf》由会员分享，可在线阅读，更多相关《Cosmo Pharmaceuticals2023年年度报告.pdf（160页珍藏版）》请在三个皮匠报告上搜索。

1、Annual Report and Accounts 2023COSMO PHARMACEUTICALS1Cosmo Pharmaceuticals Annual Report and Accounts 20235.Other Information4.Company Financial Statements3.Consolidated Financial Statements2.Directors Report1.About UsCosmo is a pharmaceutical company with a focus on gastrointestinal diseases,dermat

2、ology and healthtech We develop and manufacture products which are distributed globally by our partners1.1 What we doDelivering Innovation+Improving Lives2Cosmo Pharmaceuticals Annual Report and Accounts 20235.Other Information4.Company Financial Statements3.Consolidated Financial Statements2.Direct

3、ors Report1.About UsIn gastroenterology our focus is to improve the safety profile and efficacy of molecules that are already on the market1.1 What we do continuedCosmo has successfully identified unmet medical needs,managed the product development process and obtained regulatory approval for its pr

4、oductsWe license our approved products to partners with strong marketing and sales expertiseIn dermatology we aim to develop novel therapies which have minimal side-effectsIn healthtech we are developing cutting-edge intelligent medical devices to assist with clinical decision-making;our first devic

5、e aids endoscopists in the detection of colonic mucosal lesions3Cosmo Pharmaceuticals Annual Report and Accounts 20235.Other Information4.Company Financial Statements3.Consolidated Financial Statements2.Directors Report1.About UsOur clinical focusCosmo is a pharmaceutical company with a focus on gas

6、trointestinal diseases,dermatology and healthtech.Products which Cosmo has developed include:Lialda/Mezavant/Mesavancol and Uceris/Cortiment,for the treatment of ulcerative colitis;GI Genius,which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy;Eleview,a sub